[Treatment of neonatal respiratory distress syndrome with surfactant BL].
The paper presents the results of use of the Russian drug Surfactant BL as part of complex intensive care of respiratory distress syndrome (RDS) in the premature newborn. The drug was used in 45 children (a study group). A control group comprised 52 children with RDS who had undergone a course of therapy before the use of the drug at our clinic. Statistical analysis indicated the practical uniformity of the study and control groups. Particular emphasis was laid on the study of changes in the parameters of blood oxygenation and those of artificial ventilation (AV) regimens in both groups of children. The study demonstrated that in the Surfactant BL-treated patients, blood oxygenation (pO2, A-aDO2, respiratory coefficient) improved much more rapidly and, from the end of the first day of treatment to the termination of therapy in the intensive care unit of a maternity hospital, the mean values of these parameters remained statistically significantly better than those in the controls. In the study group, under AV, insufflated gas FiO2 could be reduced more rapidly and by a large quantity and some other AV parameters "attenuated". Analyzing the outcome of treatment of neonatal infants with RDS has indicated that Surfactant BL has a statistically significant advantage in the positive outcomes of treatment in a group of patients treated with this agent as part of complex intensive care.
Zatovka
G N
GN
Duginova
S A
SA
Safarov
A A
AA
Nechaeva
M V
MV
Blauberg
E N
EN
D001786:Blood Glucose / Q000032:analysis; D005260:Female; D005865:Gestational Age; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D008297:Male; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D016896:Treatment Outcome
D001786:Blood Glucose; D011663:Pulmonary Surfactants